Title: Internal monitoring of Clinical studies conducted in the Department of Clinical Pharmacology,

K.E.M. Hospital, Mumbai.

SOP No.: D 26/06

Date first effective: 01 Jan 2024

Review date: 31 Dec 2024

Department of Clinical Pharmacology, First floor, New MS building Seth GS Medical College & KEM

Hospital, Parel, Mumbai 400012.

Category: Departmental SOP

Title: Internal monitoring of Clinical studies conducted in the Department of Clinical

Pharmacology, Seth GS Medical College and K.E.M. Hospital, Mumbai.

SOP No.: D 26/06

Total pages: 11

Date first effective:

01 Jan 2024

Next Review date: 31 Dec 2024

Version: 06

**SOP Team** 

Author:

Dr. Rupali Mishra

DM Resident

Signature with date

Reviewer:

Dr. Mahesh Belhekar

Associate Professor

Dr. Mahesh N. Belhekar

Associate Professor Department of Clinical Pharmacology New MS Building, First Floor, Seth GS Medical College and KEM Hospital Acyarya Donde Marg, Parel, Mumbai- 400 012, India.

Approved by:

Signature with date

Dr. Nithya Gogtay

Professor and Head

Signature with date

31. 12-23

Dr. Nithya Gogtay

Professor & Head

Department of Clinical Pharmacology

1st Floor, MS Building,

Seth GS Medical College & KEM Hospital,

Parel, Mumbai - 400 012.

Page 1 of 11

Confidential

Title: Internal monitoring of Clinical studies conducted in the Department of Clinical Pharmacology,

K.E.M. Hospital, Mumbai.

**SOP No.:** D 26/06

Date first effective: 01 Jan 2024

Review date: 31 Dec 2024

Department of Clinical Pharmacology, First floor, New MS building Seth GS Medical College & KEM

Hospital, Parel, Mumbai 400012.

# **Table of Contents**

No.	Contents	Page no.
1.	Introduction	3
2.	Purpose	3
3.	Scope	3
4.	Applicable rules, regulations and guidelines	3
5.	Responsibilities	4
6.	Detailed Instructions	4
7.	Glossary	8
8.	Appendices	9
9	Abbreviations	10

Title: Internal monitoring of Clinical studies conducted in the Department of Clinical Pharmacology,

K.E.M. Hospital, Mumbai.

SOP No.: D 26/06

Date first effective: 01 Jan 2024

Review date: 31 Dec 2024

Department of Clinical Pharmacology, First floor, New MS building Seth GS Medical College & KEM

Hospital, Parel, Mumbai 400012.

## 1) Introduction:

Monitoring of clinical trials / studies is necessary to assure adequate protection of the rights, the safety and well-being of all research participants and ensure the quality and integrity of the resulting data generated.

The objectives of the monitoring procedures are to:

- Ensure that the study is being carried out in accordance with the (IEC) Institutional Ethics Committee approved protocol and as per (GCP) Good Clinical Practices guidelines
- Identify any problems and suggest / seek solutions

Overall the monitor should be seen as a supportive extension of the study team. Therefore, the monitor should not be perceived as an outside threat but part of the team and there to identify any problems affecting the conduct and quality of data collected.

## 2) Purpose:

The purpose of this SOP is to describe the principles of the monitoring services provided by the site and the monitoring procedures in clinical studies conducted at the site. This standard operating procedure has been developed in the Department of Clinical Pharmacology (DCP), Seth GS Medical College and KEM Hospital, Mumbai and aims to harmonise monitoring procedures. The responsibility for maintaining this operating procedure lies with delegated member of the research unit.

#### 3) Scope:

This SOP is limited to the internal monitoring of clinical studies/ trials conducted in the Department of Clinical Pharmacology (DCP), Seth GS Medical College and K.E.M. Hospital, Mumbai.

#### 4) Applicable rules, regulations and guidelines:

New Drugs and Clinical Trials Rules, 2019
 [https://cdsco.gov.in/opencms/export/sites/CDSCO WEB/Pdf documents/NewDrugs CTRules 2019.pdf] (Last accessed 20 Dec 2023)

Title: Internal monitoring of Clinical studies conducted in the Department of Clinical Pharmacology,

K.E.M. Hospital, Mumbai.

SOP No.: D 26/06

Date first effective: 01 Jan 2024

Review date: 31 Dec 2024

Department of Clinical Pharmacology, First floor, New MS building Seth GS Medical College & KEM

Hospital, Parel, Mumbai 400012.

 Ethical Guidelines for Biomedical and Human Research involving Human Participants, ICMR 2017.

http://www.icmr.nic.in/guidelines/ICMR Ethical Guidelines 2017.pdf (Last accessed 20 Dec 2023)

 ICH-GCP E6 (R3) Draft Guidelines dated 19th May 2023 <a href="https://database.ich.org/sites/default/files/ICH">https://database.ich.org/sites/default/files/ICH</a> E6%28R3%29 DraftGuideline 2023 0519.pdf (Last accessed 20 Dec2023)

#### 5) Responsibilities:

The Principal Investigator (PI) is responsible for complying with procedures necessary to secure the quality of every aspect of the trial. The PI is responsible for determining the level of monitoring and for enabling monitoring activities at the study site. The Study Monitor is responsible for conducting the monitoring in accordance with the pre-decided monitoring plan, Standard Operating Procedure (SOP) and regulatory requirements.

#### 6) Detailed Instructions:

#### 1) Internal Monitoring Schedule:

A pre-study, routine and close out monitoring is planned and conducted for the study. The pre-study monitoring will be conducted as soon as:

- All the necessary approvals have been obtained
- Staff recruited
- Investigational product has been delivered to site (is about to be delivered to site)
- Case record form (CRF) and source documents are ready
- Laboratory is ready to start storing study samples

The first routine monitoring visit will occur as soon as the first participant is enrolled or within 2 weeks of enrolment of the first participant. The subsequent monitoring should be done prior to sponsor/ Contract Research Organization (CRO) monitoring in case of pharma sponsored trial or

Title: Internal monitoring of Clinical studies conducted in the Department of Clinical Pharmacology,

K.E.M. Hospital, Mumbai.

SOP No.: D 26/06

Date first effective: 01 Jan 2024

Review date: 31 Dec 2024

Department of Clinical Pharmacology, First floor, New MS building Seth GS Medical College & KEM

Hospital, Parel, Mumbai 400012.

as per recruitment rate in case of investigator initiated study (IIS). The monitoring frequency may be increased if recruitment rate is faster, or at times of data entry deadlines such as interim analysis or if the Data and Safety Monitoring Board (DSMB) request a safety report.

## 1. Monitoring Procedures:

- All the team members will be informed through email before approximately a week before the scheduled monitoring visit with detailed objectives of monitoring.
- Monitoring will focus on the following key processes of the study so as to ensure protection of rights, safety and well-being of study participants and integrity of data:
  - i. Informed consent process and documents
  - ii. Study eligibility criteria met for all participants
- iii. Source data verification
- iv. Completion of Study CRFs.
- v. Accurate entry of data from clinical and laboratory forms.
- vi. Sample collection and handling in accordance to Protocol and SOP(s)
- vii. Review of data management procedure i.e. data entry, handling of data discrepancies and data backup. (If applicable)
- viii. Reporting of adverse events and protocols deviations and violations according to SOP(s)
- ix. Investigational Product accountability
- x. Follow up assessments and procedures
- xi. Measures to ensure complete participant follow up.
- xii. Maintenance and regular update of trial master file(s)
- During each monitoring, the monitor will work according to an agreed schedule of tasks,
   including the following that will be given as specifics in the monitoring form

Title: Internal monitoring of Clinical studies conducted in the Department of Clinical Pharmacology,

K.E.M. Hospital, Mumbai.

SOP No.: D 26/06

Date first effective: 01 Jan 2024 Review date: 31 Dec 2024

Department of Clinical Pharmacology, First floor, New MS building Seth GS Medical College & KEM

Hospital, Parel, Mumbai 400012.

- Schedule a date with the study investigator/coordinator for the monitoring procedure and provide them with a list or shell of the study sections that will be monitored in the particular visit
- Review last monitoring report(s)
- Review the trial master file (TMF) to ensure that it is updated
- Verify correct version of written informed consent documents were given for every subject enrolled into the study and obtained according to the consent SOP
- Review current status of the study participants enrolled vs. anticipated enrolled, lost to follow up, outstanding data issues, reported SAEs, outstanding laboratory issues
- Review the enrolled participants file to verify that the participants were eligible
- Review the safety issues and protocol violations or deviations (if any)
- Review the reports of all investigations done during study
- Review the screening and enrolment log
- Review all EC and sponsor (if applicable) communications
- Review laboratory documents: handling, storage and shipment of samples.
- Review Investigational Product (IP) accountability log: handling, storage, usage and shipment of IPs
- Source data verification entry of data from clinical and laboratory forms.
- During the initial visits the monitors will review 100% of the fields of all the study forms. All forms monitored during a visit will be detailed in the monitoring report (See appendix 2)
- After each monitoring visit the monitor will debrief the study team i.e. appreciate them where they are getting it right and highlight areas which need improvement
- The monitor will then write up a monitoring report citing all findings and status of such findings (resolved or not) and forward the copy [both soft copy and hard copy] to the PI

Title: Internal monitoring of Clinical studies conducted in the Department of Clinical Pharmacology,

K.E.M. Hospital, Mumbai.

SOP No.: D 26/06

Date first effective: 01 Jan 2024 Review

Review date: 31 Dec 2024

Department of Clinical Pharmacology, First floor, New MS building Seth GS Medical College & KEM Hospital, Parel, Mumbai 400012.

• The follow up monitoring will be conducted within four days to ensure that the findings arise during the previous monitoring are resolved

• For IIS, at close out visit(s) the monitor will ensure all queries are resolved and study documents are properly archived. The comprehensive list of activities during this visit(s) will be detailed in a study close out SOP.

## 7) Glossary:

## a) Monitoring

The act of overseeing the progress of a clinical study, and of ensuring that it is conducted, recorded, and reported in accordance with the protocol, SOPs, Good Clinical Practice (GCP), and the applicable regulatory requirement(s).

## b) Trial Master File (TMF):

The repository for the essential documents for the conduct of a clinical trial. These documents individually and collectively permit evaluation of the conduct of the study and the quality of the data produced. These documents demonstrate the compliance of the sponsor-investigator and of the monitor with standards of GCP and with all applicable regulatory requirements.

#### c) SOP (Standard Operating Procedure)

Standard Operating Procedures (SOP) are detailed, written instructions, in a certain format, describing activities and actions undertaken by an organisation to achieve uniformity of the performance of a specific function. The aim of the SOPs and their accompanying checklists and forms is to simplify the functioning, whilst maintaining high standards of Good Clinical Practice.

Title: Internal monitoring of Clinical studies conducted in the Department of Clinical Pharmacology,

K.E.M. Hospital, Mumbai.

**SOP No.:** D 26/06

Date first effective: 01 Jan 2024

Review date: 31 Dec 2024

Department of Clinical Pharmacology, First floor, New MS building Seth GS Medical College & KEM

Hospital, Parel, Mumbai 400012.

## 8) Appendices:

# 1) Checklist for monitoring:

Sr. No.	Issues reviewed/discussed during visit	Yes	No	N/AP
1	Screening & Enrolment log			
2	Subject-Informed Consent form and narrative			
3	CRFs and source documents verification			
4	Protocol deviations/violations			1
5	Trial Master File	11012		
6	Study medication, Randomisation & Blinding Codes-if			
	Applicable	." <u>!</u> 26	1977	E TALLY
7	AE / SAE Reporting.			
8	Amendments in study documents	un cu qu		
9	Study team			
10	Site Facilities			
11	Laboratory Issues	21 100 2		- 215
12	Collections of CRFs		i iga-	
13	Queries			
14	Miscellaneous			
15	Follow-up action points previous visit(s)			-
16	IP accountability log			

Title: Internal monitoring of Clinical studies conducted in the Department of Clinical Pharmacology,

K.E.M. Hospital, Mumbai.

**SOP No.:** D 26/06

Date first effective: 01 Jan 2024

Review date: 31 Dec 2024

Department of Clinical Pharmacology, First floor, New MS building Seth GS Medical College & KEM

Hospital, Parel, Mumbai 400012.

# 2) Monitoring report format:

Study Title	×
Protocol ID	
Investigator Name	
Institution	
Address	
Monitor Name	
Date of visit	
Study staff seen	

#### Sub 1. Subject Screening & Enrollment

## Sub 2. Subject Informed Consent

#### Sub 3. CRFs and source documents verification

Screening No	Findings	Correction Done	Follow Up Required
/ Subject ID		(Yes/No)	(Yes/No)
		A section of the sect	2010/04/04/04/04/04/04/04/04/04/04/04/04/04
			Section 1988

Title: Internal monitoring of Clinical studies conducted in the Department of Clinical Pharmacology,

K.E.M. Hospital, Mumbai.

**SOP No.:** D 26/06

Date first effective: 01 Jan 2024

Review date: 31 Dec 2024

Department of Clinical Pharmacology, First floor, New MS building Seth GS Medical College & KEM

Hospital, Parel, Mumbai 400012.

## Sub 4. Site Master File

SI No:	Findings	Correction Done	Follow Up Required
		(Yes/No)	(Yes/No)

Prepared by:	
Name	Signature & Date

#### 9. Abbreviations:

- i. AE: Adverse Event
- ii. CRF: Case Record Form
- iii. CRO: Contract Research Organization
- iv. DCP: Department of Clinical Pharmacology
- v. DSMB: Data and Safety Monitoring Board
- vi. GCP: Good Clinical Practices
- vii. ID: Identification
- viii. IEC: Institutional Ethics Committee
- ix. IIS: Investigator Initiated Study
- x. IP: Investigational Product
- xi. SAE: Serious Adverse Event
- xii. SOP: Standard Operating Procedure
- xiii. TMF: Trial Master File

Title: Internal monitoring of Clinical studies conducted in the Department of Clinical Pharmacology,

K.E.M. Hospital, Mumbai.

SOP No.: D 26/06

Date first effective: 01 Jan 2024

Review date: 31 Dec 2024

Department of Clinical Pharmacology, First floor, New MS building Seth GS Medical College & KEM

Hospital, Parel, Mumbai 400012.

Reviewer:

Dr. Mahesh Belhekar

Associate Professor

Associate Professor

Department of Clinical Pharmacology New MS Building, First Floor, Seth GS Medical College and KEM Hospital

Acyarya Donde Marg, Parel, Mumbai- 400 012, India.

Signature with date

Approved by:

Dr. Nithya Gogtay

Professor and Head

Signature with date

rofessor & Hand Professor & Head Department of Clinical Pharmacology 1" Floor, MS Building, Seth GS Medical College & KEM Hospital,

i - 400 012.